Clinical development of nafarelin acetate. Phase I and phase II studies.
D000281:Administration, Intranasal; D001682:Biological Availability; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D017274:Nafarelin; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011629:Puberty, Precocious / Q000188:drug therapy; D013739:Testosterone / Q000097:blood
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone